Desmosine, a biomarker for COPD: Old and in the way

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 297-298

  Luisetti, M ^a   Stolk, J ^c   Iadarola, P ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DESMOSINE; ELASTIN; ISODESMOSINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; EDITORIAL; FORCED EXPIRATORY VOLUME; LUNG FUNCTION; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; FEMALE; HUMAN; LUNG; MALE; NOTE; PHYSIOLOGY; URINE;

DESMOSINE; FEMALE; HUMANS; ISODESMOSINE; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84864538176     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00172911     Document Type: Editorial

References (17)

1. Cazzola M, McNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-468.
2. Gelb AF, Hogg JC, Muller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996; 109: 353-359. (Pubitemid 26058588)
3. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
4. DeGruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a national institutes of health workshop. Control Clin Trials 2001; 22: 485-502. (Pubitemid 32907433)
5. Barnes PJ, Chowdury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6-14. (Pubitemid 43955238)
6. Viglio S, Annovazzi L, Luisetti M, et al. Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation. J Sep Sci 2007; 30: 202-231.
7. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146-1157.
8. Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 2007; 62: 657-660. (Pubitemid 47235002)
9. Lindberg CA, Engström G, Gerhardsson de Verdier M, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39: 839-845.
10. Ma S, Lin YY, Turino GM. Measurement of desmosine and isodesmosine by mass spectrometry in COPD. Chest 2007; 131: 1363-1371. (Pubitemid 46762340)
11. Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J 1993; 7: 1208-1218. (Pubitemid 23314355)
12. Foster JA, Curtiss SW. The regulation of lung elastin synthesis. Am J Physiol 1990; 259: L13-L23. (Pubitemid 20257228)
13. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J COPD 2008; 3: 253-268. (Pubitemid 352037885)
14. Shapiro SD, Ingento EI. Pathogenesis of chronic obstructive pulmonary disease. Advances in the past 100 years. Am J Respir Cell Mol Biol 2005; 32: 367-372. (Pubitemid 40629320)
15. Carter RI, Mumford RA, Treonze KM, et al. The fibrinogen cleavage product Aa-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax 2011; 66: 686-691.
16. Turino GM, Ma S, Lin YY, et al. Matrix elastin. A promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 637-641.
17. Fregonese L, Ferrari F, Fumagalli F, et al. Long-term variability of desmosine/isodesmosine as biomarker in a1-antitrypsin deficiencyrelated COPD. COPD 2011; 8: 329-333.